Literature DB >> 27738363

Antipsychotic Induced Symptomatic Hyperprolactinemia: Are Dopamine Agonists Safe?

Unax Lertxundi1, Saioa Domingo-Echaburu1, Javier Peral1, Montserrat García1.   

Abstract

Published literature shows that dopamine agonists can reverse antipsychotic-induced hyperprolactinemia without worsening psychotic symptoms in the majority of schizophrenic patients. However, psychiatrists have been reluctant to use drugs with dopaminergic properties for fear of exacerbating psychiatric symptoms. There are reported cases of psychosis worsening published for both cabergoline and bromocriptine. Cabergoline has proven to be more effective and safe when used to treat hyperprolactinemia, but whether cabergoline is also safer than bromocriptine in antipsychotic induced hyperprolactinemia remains unproven.

Entities:  

Keywords:  Antipsychotic; Bromocriptine; Cabergoline; Hyperprolactinemia; Pharmacovigilance

Year:  2011        PMID: 27738363      PMCID: PMC5044550     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  8 in total

1.  Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia.

Authors:  Norio Yasui-Furukori; Hanako Furukori; Norio Sugawara; Akira Fujii; Sunao Kaneko
Journal:  J Clin Psychopharmacol       Date:  2010-10       Impact factor: 3.153

Review 2.  Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis.

Authors:  Vania dos Santos Nunes; Regina El Dib; César Luiz Boguszewski; Célia Regina Nogueira
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

3.  Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study.

Authors:  Moon-Soo Lee; Hyun-Cheol Song; Hyonggin An; Jaewon Yang; Young-Hoon Ko; In-Kwa Jung; Sook-Haeng Joe
Journal:  Psychiatry Clin Neurosci       Date:  2009-11-24       Impact factor: 5.188

4.  Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect.

Authors:  Giorgio Marchese; Stefania Ruiu; Paola Casti; Francesco Bartholini; Pierluigi Saba; Gian Luigi Gessa; Luca Pani
Journal:  Eur J Pharmacol       Date:  2002-06-28       Impact factor: 4.432

5.  Cabergoline-induced psychotic exacerbation in schizophrenic patients.

Authors:  Shen-Chieh Chang; Chun-Hsin Chen; Mong-Liang Lu
Journal:  Gen Hosp Psychiatry       Date:  2008 Jul-Aug       Impact factor: 3.238

6.  Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study.

Authors:  Roberto Cavallaro; Federica Cocchi; Sara M Angelone; Enrico Lattuada; Enrico Smeraldi
Journal:  J Clin Psychiatry       Date:  2004-02       Impact factor: 4.384

Review 7.  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Authors:  Peter M Haddad; Angelika Wieck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Psychotic exacerbation attributed to low-dose bromocriptine treatment of galactorrhea and hyperprolactinemia.

Authors:  A Dorevitch; R Aronzon; M Stark
Journal:  Acta Obstet Gynecol Scand       Date:  1991       Impact factor: 3.636

  8 in total
  2 in total

1.  Effect of Peony-Glycyrrhiza Decoction on Amisulpride-Induced Hyperprolactinemia in Women with Schizophrenia: A Preliminary Study.

Authors:  Ping Yang; Liang Li; Dong Yang; Chaoying Wang; Hongli Peng; Huiyong Huang; Xuejun Liu
Journal:  Evid Based Complement Alternat Med       Date:  2017-11-26       Impact factor: 2.629

2.  Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial.

Authors:  Cuifang Zhu; Ruofan Li; Mingliang Ju; Xudong Xiao; Ti-Fei Yuan; Zhixing Jin; Jing Zhao
Journal:  Front Mol Neurosci       Date:  2022-05-26       Impact factor: 6.261

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.